Axxess Pharma, Inc. AXXE
We’re putting AXXE on our radars this morning, a new play with a chart that appears to have potential. As always when we focus on a new company, we’d first like to take a few minutes to familiarize ourselves with the business behind the stock.
Axxess Pharma has an expansive line which includes twenty-three prescription and non-prescription strength products, which are used in the treatment of a variety of ailments, including but not limited to: iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, and joint pain.
The company has been taking steps to make these products available to the public at an affordable price.
AXXE recently signed an agreement with a Mexican pharma company that will facilitate the distribution of its Soropon product to the Mexican population, which, according to President and CEO Dr. Daniel Bagi, is ” three times that of Canada’s and has a higher birth rate than Canada. AXXE is extremely pleased with the market possibilities in Mexico for Soropon and we anticipate robust sales for Soropon in Mexico, starting in 2014.”
That and more was covered yesterday when we conducted an Exclusive Interview with Dr. Bagi via our sister site, Stock Traders Talk. It covered a lot of important things, so be sure to take a few minutes to check that out on StockTradersTalk.com when it becomes available this afternoon!
Now to go over the AXXE chart, for which we’ve provided the following video presentation:
Axxess has been awfully busy of late, making several news announcements already this month. Between its active approach to shareholder outreach via press release, as well as the CEO making the time to take part in our interview, we can see that this company places a high emphasis on transparency and visibility. To that end, if you read ahead to the PRs, we find that AXXE is actually making preparations for an uplisting to the OTC Bulletin Board.
SEPTEMBER PRESS RELEASES:
More Info is available at: